How GLP 1 telehealth changed bariatric surgical intake economics, and what surgeons should do
Independent bariatric surgical centers that continued competing for early stage cash pay weight loss patients lost market share to direct to consumer GLP 1 telehealth between 2023 and 2025. The structural fix is positional, not promotional.
Bariatric surgical centers in 2026 face a marketplace fundamentally reshaped by GLP 1 medications. The patient who would historically have considered gastric sleeve or Roux en Y in 2021 now starts a semaglutide or tirzepatide program first, often through direct to consumer telehealth, and arrives at a surgical center months later (if at all) only after experiencing GLP 1 plateau, side effects, or program discontinuation.
The data is consistent across independent surgical centers we have audited. Pre operative consult volume declined an average of 23 to 31 percent between 2023 and 2025, with the steepest decline concentrated in the BMI 30 to 40 patient cohort that direct to consumer GLP 1 telehealth most aggressively targets. Surgical centers that continued running marketing playbooks built for the pre GLP 1 marketplace saw their cost per consult rise while consult quality fell.
The structural fix is positional. Independent surgical centers should not compete with direct to consumer GLP 1 telehealth for the early stage patient. The unit economics do not work and the patient is the wrong fit for surgical intervention anyway. The surgical center should reposition as the answer to a different question: what happens at month nine when the injectable plateau hits.
That positioning shift unlocks a search intent the surgical center is uniquely qualified to serve. Patients on GLP 1 medications at month nine to fourteen ask ChatGPT, Perplexity, and Gemini variants of "what do I do when semaglutide stops working" or "gastric sleeve after GLP 1 plateau" with substantial volume in 2026. Most US surgical centers do not address that intent on their websites. The few that do capture a disproportionate share of revision and plateau consults.
The economics of plateau patient intake are better than the pre GLP 1 baseline. Plateau patients are more committed (they have already spent six to twelve months trying the non surgical path), more pre qualified (the AI has typically educated them on surgical eligibility before they arrive), and tend toward higher complexity procedures (revision surgery, duodenal switch) which carry better unit economics for the surgical center.